

CESCA THERAPEUTICS INC.  
Form 8-K  
November 22, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): November 17, 2016

**CESCA THERAPEUTICS INC.**

(Exact name of registrant as specified in its charter)

<u>Delaware</u>	<u>333-82900</u>	<u>94-3018487</u>
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

2711 Citrus Road

Rancho Cordova, California 95742

Edgar Filing: CESCA THERAPEUTICS INC. - Form 8-K

(Address and telephone number of principal executive offices) (Zip Code)

(916) 858-5100

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

99.1 Transcript dated November 17, 2016 for conference call titled, "Cesca Therapeutics Inc. Reports Fiscal 2017 First Quarter Financial Results Conference Call".

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Cesca Therapeutics Inc.**  
a Delaware Corporation

Dated:  
November /s/ Michael Bruch  
22, 2016

Michael Bruch  
Chief Financial Officer